Prostate cancer ranks as a substantial worldwide medical distress because traditional tests, including prostate-specific antigen (PSA) screening and digital rectal examination (DRE), fall short in diagnosing the disease. The changing biomarker environment and its vital function for advancing prostate cancer diagnosis form the primary subject of this chapter. Traditional diagnostic methods show key limitations, while patients require better, more precise, and non-aggressive diagnostic tools that replace current inadequate procedures. This section conducts a thorough evaluation of current and prospective biomarkers, organizing them based on their origins in serum, tissue, and urine, as well as their diagnostic, predictive, and prognostic functions. We critically analyze the real-world value of biomarkers PCA3 and TMPRSS2-ERG fusion and various genomic test approaches, as well as their positions in diagnostic decision tools. This chapter also evaluates upcoming biomarkers, including circulating tumor cells, exosomes, and epigenetic markers, to enhance the capability of early identification and risk assessment, and minimize non-compliant biopsy practices. Modern biomarker research requires multi-panel biomarker examinations and personalized diagnosis techniques to achieve exact patient-centric prostate cancer diagnosis strategies, according to this chapter.